SBC Medical Group (NASDAQ:SBC) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded SBC Medical Group from “strong buy” to “buy.” Despite the change, MarketBeat reports a “Moderate Buy” consensus rating and an average price target of $8.
• SBC beat quarterly estimates, reporting EPS of $0.15 versus $0.12 expected and revenue of $58.58 million versus $48.90 million expected.
• Institutional investors own 60.82% of the company’s shares; several firms, including BlackRock and Marshall Wace, recently established new positions.

SBC Medical Group (NASDAQ:SBC - Get Free Report) was downgraded by analysts at Wall Street Zen from a "strong-buy" rating to a "buy" rating in a research note issued to investors on Saturday, Wall Street Zen reports.

SBC has been the topic of several other research reports. BTIG Research reissued a "buy" rating and set a $8.00 price target on shares of SBC Medical Group in a research report on Thursday, August 13th. Weiss Ratings raised shares of SBC Medical Group from a "hold (c-)" rating to a "hold (c)" rating in a report on Friday, October 9th. One investment analyst has rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $8.00.

SBC Medical Group Stock Performance

Shares of SBC Medical Group stock opened at $7.35 on Friday. SBC Medical Group has a one year low of $2.78 and a one year high of $7.39. The company has a market cap of $755.95 million, a price-to-earnings ratio of 11.36, a PEG ratio of 2.40 and a beta of 0.52. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.27 and a current ratio of 3.31. The business's 50 day moving average price is $5.13 and its 200 day moving average price is $3.98.

SBC Medical Group (NASDAQ:SBC - Get Free Report) last issued its earnings results on Friday, November 13th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.03. SBC Medical Group had a return on equity of 18.47% and a net margin of 27.99%. The company had revenue of $58.58 million during the quarter, compared to analysts' expectations of $48.90 million. On average, research analysts predict that SBC Medical Group will post 0.44 EPS for the current year.

Institutional Trading of SBC Medical Group

Institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in SBC Medical Group in the second quarter valued at approximately $2,846,000. Russell Investments Group Ltd. increased its stake in SBC Medical Group by 2,810.4% during the third quarter. Russell Investments Group Ltd. now owns 125,991 shares of the company's stock worth $622,000 after acquiring an additional 121,662 shares during the last quarter. Marshall Wace LLP acquired a new stake in SBC Medical Group during the third quarter worth $520,000. Citadel Advisors LLC purchased a new stake in SBC Medical Group in the second quarter valued at $446,000. Finally, State Street Corp raised its position in SBC Medical Group by 58.9% in the third quarter. State Street Corp now owns 78,232 shares of the company's stock valued at $386,000 after purchasing an additional 28,993 shares during the period. Hedge funds and other institutional investors own 60.82% of the company's stock.

Recent SBC Medical Group Headlines

These are some of the SBC headlines that stood out recently:

• Positive Sentiment: Third-quarter revenue rose 35% to $58.6 million, ahead of the $48.9 million analyst estimate. EPS of $0.15 also beat the $0.12 consensus. Net income attributable to SBC increased 22% to $15.7 million, while adjusted EBITDA rose 66% year over year. SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Growth was supported by higher management-services revenue, service-fee revisions and the consolidation of Waqoo. The clinic network expanded to 293 locations, up 36 from a year earlier; the company reported $198.4 million in cash at quarter-end. SBC Medical Q3 Revenue Rises 35% to $58.6 Million
• Positive Sentiment: SBC announced a capital and business alliance with NeuroBrain Dynamics, a generative-AI company, with the stated goal of using medical AI to improve clinic profitability. The financial impact and rollout details were not disclosed. SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics

SBC Medical Group Company Profile

SBC Medical Group Holdings provides management and support services to medical institutions, with a focus on clinics offering aesthetic medicine. Its services include support for clinic operations, marketing, staff training, procurement and customer service, allowing affiliated medical providers to focus on patient care. The group is associated with the Shonan Beauty Clinic brand and a broader network of clinics offering services such as cosmetic surgery and dermatology. Its business is centered primarily in Japan, where it supports the operations and growth of affiliated medical institutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.